Introduction

Pfizer Inc. is an American multinational pharmaceutical corporation founded in 1849 and headquartered in New York City. It is one of the world's largest pharmaceutical companies.

Within the framework of the Pfizer Covid-19 Vaccine Grants programme, funding is available to support independent efforts in areas of research, education and quality improvement in relation to Pfizer's COVID-19 vaccine. The programme is launched in phases, but will eventually consist of the following areas:

• Covid-19 Vaccine General Research: the following areas of research will be considered:
  • Studies evaluating COVID-19 burden of disease and sero-epidemiological surveys among specific populations.
  • Epidemiology studies evaluating direct and indirect impact, including modeling approaches, of Pfizer's vaccine particularly in specific patient populations.
  • Studies measuring the impact of efforts to overcome vaccine hesitancy and enhance vaccine uptake.
• (Not open yet) Covid-19 Vaccine Independent Medical Education: optimise the prevention of COVID-19 by:
• Increase awareness of the risk of COVID-19 for all ages and racial and ethnic groups.
• Increase the understanding, and familiarity with, the proper storage, handling and administration of Pfizer's vaccine.
• (Published as a RFP) Covid-19 Vaccine Population Health: optimise the prevention of COVID-19 by increasing the understanding and familiarity with COVID-19 and Pfizer's COVID-19 vaccine among the general population.

Budget

No maximum grant amounts are given.

Eligibility

Researchers worldwide are eligible.

Application

Applications may be submitted through the online application system. There is no deadline.

In case of interest, please contact lnorton(ELIMINAR)@fsjd.org